Hurukan 150 mg (Fluconazole)

Adult dose

The route of administration should be determined according to the patient's clinical condition. Because absorption of the oral formulation is rapid and nearly complete, the doses of oral formulations (tablets, capsules, dry syrup) and injectable formulations are the same. ○ Adults 1. Vaginal candidiasis: Administer a single 150 mg oral dose of fluconazole. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): The usual dose of this drug is 400 mg once on the first day, followed from the next day by 200 mg once daily. The dose may be increased to 400 mg once daily according to the patient's response. The duration of treatment is determined according to clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose of this drug is 400 mg once on the first day, followed from the next day by 200-400 mg once daily. The duration of treatment is determined by clinical and mycological response, but treatment should usually continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg of this drug once daily indefinitely after the patient has completed all primary treatment. 5. Prevention of fungal infections in immunocompromised patients at risk of fungal infections due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this drug once daily according to the patient's risk of fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infection, such as those undergoing bone marrow transplantation, who have severe neutropenia or are expected to have prolonged neutropenia. In these patients, administer 400 mg starting 5-6 days before the expected onset of neutropenia, and continue administering 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or higher. 6. For onychomycosis, administer 150 mg once weekly until the fingernails or toenails have regrown (until new, uninfected nails have grown). New fingernails usually take 3-6 months to grow, and toenails take about 6-12 months; growth rates may vary between individuals according to age. Even after successful treatment with long-term administration, the fingernails or toenails may sometimes remain damaged. For cutaneous fungal infections, including athlete's foot (tinea pedis), tinea corporis, jock itch (tinea cruris), and cutaneous candidiasis: The usual dose of this drug is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, treatment of athlete's foot may need to continue for 6 weeks, depending on the course of the disease. For tinea versicolor, administer 50 mg once daily for 2-4 weeks. ○ Elderly patients If renal function is normal, the usual adult dose may be administered. If renal impairment is present (creatinine clearance 50 mL/min or less), the dose should be reduced or the dosing interval extended. ○ Patients with renal impairment This drug is excreted mainly in the urine unchanged. No dosage adjustment is necessary for a single dose, but if multiple doses are required, administer the usual dose only on the first day and adjust the dose from the next day as follows. Creatinine clearance (mL/min) / Recommended dose > 50: 100 % of the usual dose ≤50 (not on dialysis): 50% of the usual dose Patients on hemodialysis: 100% of the usual dose after each hemodialysis session Patients undergoing hemodialysis should receive 100% of the usual dose after each hemodialysis session. On days when dialysis is not performed, administer a reduced dose according to creatinine clearance.

This medication should not be administered to certain patients. First, patients who have experienced allergic reactions to this medication or similar types of drugs should not use it. Women who are pregnant or may become pregnant, as well as nursing mothers, should also avoid taking this medication. Serious side effects may occur when taken with certain medications, so patients currently taking any medications must consult with their physician or pharmacist. This medication contains lactose, so patients with lactose intolerance should take caution. Patients with problems in kidney or liver function, or those with heart disease or electrolyte imbalances, should be especially cautious when using this medication. Patients with a history of drug hypersensitivity also need to be careful. This medication may affect liver and kidney function, so regular checks are required during treatment to monitor the condition. Patients with heart disease need to be particularly cautious due to the risk of heart rhythm disorders. While this medication is generally safe, it may rarely cause abnormalities in blood or liver function, skin rashes, or gastrointestinal symptoms. If severe skin rashes or breathing difficulties occur, patients should inform healthcare professionals immediately. Pregnant women should avoid taking this medication as it can be harmful to the fetus and should strictly practice contraception; it should never be used during pregnancy. Nursing mothers should also avoid taking this medication as it can be transmitted through breast milk. The safety of this medication has not been established in pediatric patients, particularly in infants under 6 months of age, and it should be used with caution only in necessary cases. This medication may cause dizziness or seizures while driving or operating machines, so caution is advised. In cases of overdose, hallucinations or abnormal behavior may occur, so immediate medical assistance should be sought, and appropriate treatment such as hemodialysis should be provided as necessary. This medication has many drug interactions, so patients taking other medications must consult healthcare professionals to ensure it is used safely.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, sensory disturbances, taste disturbances, tremors, vertigo, Torsades de Pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, flatulence, dry mouth, ALT increase, AST increase, increased serum alkaline phosphatase, cholestasis, jaundice, elevated bilirubin, hepatotoxicity, hepatic failure, hepatocellular necrosis, hepatitis, hepatocyte damage, rash, itching, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial edema, alopecia, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, lethargy, weakness, fever, adrenal insufficiency, hallucinations, disordered behavior

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage helps to maintain the effectiveness of the medication for an extended period.

Appearance

Pink oblong tablet

Package unit

30 tablets/bottle